{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:29:50Z","timestamp":1775381390688,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1124\/jpet.123.002051","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T21:55:11Z","timestamp":1708984511000},"page":"96-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability"],"prefix":"10.1016","volume":"389","author":[{"given":"Wenqiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney C.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael W.","family":"Sirianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.002051_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/ed071p715","article-title":"The hydrolysis of p-nitrophenyl acetate: a versatile reaction to study enzyme kinetics","volume":"71","author":"Anderson","year":"1994","journal-title":"J Chem Educ"},{"key":"10.1124\/jpet.123.002051_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of area under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.123.002051_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny","year":"2014","journal-title":"Med Oncol"},{"key":"10.1124\/jpet.123.002051_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1124\/jpet.123.002051_bib5","series-title":"Medical Epigenetics","first-page":"633","article-title":"Histone deacetylase inhibitors in medical therapeutics","author":"Chun","year":"2016"},{"key":"10.1124\/jpet.123.002051_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-012-1940-9","article-title":"Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients","volume":"70","author":"Clive","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.123.002051_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J"},{"key":"10.1124\/jpet.123.002051_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.123.002051_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/bc5005747","article-title":"Effect of attachment site on stability of cleavable antibody drug conjugates","volume":"26","author":"Dorywalska","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1124\/jpet.123.002051_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpba.2006.05.005","article-title":"Stability studies of vorinostat and its two metabolites in human plasma, serum and urine","volume":"42","author":"Du","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/jpet.123.002051_bib11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1021\/tx200237a","article-title":"Production of ES1 plasma carboxylesterase knockout mice for toxicity studies","volume":"24","author":"Duysen","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.123.002051_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00498251003706598","article-title":"Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor","volume":"40","author":"Eng","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.123.002051_bib13","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1021\/jm900648x","article-title":"Hydroxamates: relationships between structure and plasma stability","volume":"52","author":"Flipo","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.002051_bib14","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.123.002051_bib15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.apsb.2022.10.017","article-title":"Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism","volume":"13","author":"Gan","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.123.002051_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2174\/138955710791384081","article-title":"Bioavailability challenges associated with development of anti-cancer phenolics","volume":"10","author":"Gao","year":"2010","journal-title":"Mini Rev Med Chem"},{"key":"10.1124\/jpet.123.002051_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/jpet.123.002051_bib18","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: a MedChem toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.002051_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1124\/dmd.112.048397","article-title":"Carboxylesterases are uniquely expressed among tissues and regulated by nuclear hormone receptors in the mouse","volume":"41","author":"Jones","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.002051_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.123.002051_bib21","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.123.002051_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2008.05.001","article-title":"In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors","volume":"361","author":"Konsoula","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1124\/jpet.123.002051_bib23","first-page":"615","article-title":"Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1124\/jpet.123.002051_bib24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.002051_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jpba.2019.02.004","article-title":"Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat","volume":"168","author":"Li","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/jpet.123.002051_bib26","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/foc.2005.19.5.11","article-title":"Epigenetic events in medulloblastoma development","volume":"19","author":"Lindsey","year":"2005","journal-title":"Neurosurg Focus"},{"key":"10.1124\/jpet.123.002051_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/antiox10020256","article-title":"Human paraoxonase-2 (PON2): protein functions and modulation","volume":"10","author":"Manco","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1124\/jpet.123.002051_bib28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1124\/jpet.123.002051_bib29","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1158\/1078-0432.CCR-10-0395","article-title":"HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth","volume":"16","author":"Milde","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.123.002051_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fonc.2015.00148","article-title":"Future clinical trials in DIPG: bringing epigenetics to the clinic","volume":"5","author":"Morales La Madrid","year":"2015","journal-title":"Front Oncol"},{"key":"10.1124\/jpet.123.002051_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1124\/dmd.30.5.534","article-title":"Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes","volume":"30","author":"Nakamura","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.002051_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.122.001268","article-title":"Murine CNS and bone marrow distribution of the aurora A kinase inhibitor alisertib: pharmacokinetics and exposure at the sites of efficacy and toxicity","volume":"383","author":"Oh","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 5","key":"10.1124\/jpet.123.002051_bib33","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1124\/jpet.123.002051_bib34","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noz089","article-title":"A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma","volume":"21","author":"Pak","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1124\/jpet.123.002051_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.123.002051_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"10.1124\/jpet.123.002051_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.123.002051_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.123.002051_bib39","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-13-1759","article-title":"P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice","volume":"20","author":"Tang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.123.002051_bib40","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1158\/1535-7163.MCT-18-0329","article-title":"Unraveling the interaction between carboxylesterase 1c and the antibody-drug conjugate SYD985: improved translational PK\/PD by using Ces1c knockout mice","volume":"17","author":"Ubink","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.123.002051_bib41","unstructured":"Wen Z, Huang Y, Behler N, Bambal R, Bhoopathy S, Owen A (2010) Determination of red blood cell partitioning and whole blood to plasma ratio using human, rat, and mouse blood: Methods, model-compounds, and specific differences. Poster W4305 at the AAPS 2010 Annual Meeting."},{"key":"10.1124\/jpet.123.002051_bib42","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jnen\/nlx088","article-title":"LBH589 inhibits glioblastoma growth and angiogenesis through suppression of HIF-1\u03b1 expression","volume":"76","author":"Yao","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/jpet.123.002051_bib43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.123.002051_bib44","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jps.23557","article-title":"Propagation of error in ocular pharmacokinetic parameters estimate of azithromycin in rabbits","volume":"102","author":"You","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.002051_bib45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jps.2600820718","article-title":"Estimation of variance for AUC in animal studies","volume":"82","author":"Yuan","year":"1993","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.002051_bib46","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.123.001826","article-title":"CNS distribution of panobinostat in preclinical models to guide dosing for pediatric brain tumors","author":"Zhang","year":"2023","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.002051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:18:19Z","timestamp":1739978299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524172291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022356524172291"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.002051","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.002051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}